Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 5:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 195 matching trials from the live ClinicalTrials.gov search.
Conditions
Breast Cancer
Interventions
therapeutic autologous dendritic cells, aromatase inhibition therapy, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, gene expression analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, radiation therapy
Biological · Drug · Genetic + 3 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Tampa, Florida • Omaha, Nebraska
Conditions
Prostate Cancer
Interventions
Autologous dendritic cells transfected with amplified tumor RNA
Biological
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Treatment of Type I Diabetes Mellitus.
Interventions
Biological
Biological
Lead sponsor
DiaVacs, Inc.
Industry
Eligibility
12 Years to 35 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia, Early Relapse of Acute Myeloid Leukemia, Late Relapse of Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Myeloid Leukemia, Adult Acute Lymphoblastic Leukemia, Interleukin-3 Receptor Subunit Alpha Positive, Minimal Residual Disease, Refractory Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
cyclophosphamide, Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes, laboratory biomarker analysis, Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes, Fludarabine Phosphate
Drug · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Duarte, California
Conditions
Brain Tumors
Interventions
DC/AAT, DC/AAT-Flu, DC/KLH
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Conditions
Neuroblastoma, Ewings Sarcoma, Osteogenic Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma
Interventions
Autologous dendritic cell vaccine with adjuvant
Biological
Lead sponsor
University of Louisville
Other
Eligibility
1 Year to 24 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Advanced Renal Cell Carcinoma, Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions
Standard Treatment, AGS-003
Drug · Biological
Lead sponsor
Argos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
88
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • La Jolla, California + 71 more
Conditions
Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Adenosquamous Carcinoma
Interventions
Autologous DC Therapy
Biological
Lead sponsor
Diakonos Oncology Corporation
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Houston, Texas
Conditions
Lung Cancer
Interventions
autologous tumor cell vaccine, therapeutic autologous dendritic cells, conventional surgery
Biological · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Melanoma (Skin)
Interventions
autologous dendritic cell-tumor fusion vaccine, gp100 antigen, therapeutic autologous dendritic cells
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Prostate Cancer
Interventions
sipuleucel-T
Biological
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
12
States / cities
La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 5 more
Conditions
Renal Cell Carcinoma
Interventions
AGS-003
Biological
Lead sponsor
Argos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 5 more
Conditions
HIV Infections
Interventions
Autologous Dendritic Cell HIV Vaccination
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Phase 2 Interventional Results available

DC Migration Study for Newly-Diagnosed GBM

NCT02366728
Conditions
Glioblastoma, Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme
Interventions
Unpulsed DCs, Td, Human CMV pp65-LAMP mRNA-pulsed autologous DCs, 111In-labeled DCs, Temozolomide, Saline, Basiliximab
Biological · Drug
Lead sponsor
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Other
Eligibility
18 Years to 80 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Stage III Ovarian Carcinoma, Stage IV Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
Interventions
AVOVA-1, MC
Biological
Lead sponsor
Aivita Biomedical, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
6
States / cities
Burbank, California • La Jolla, California • Newport Beach, California + 2 more
Conditions
Acute Myeloid Leukemia (AML)
Interventions
G-CSF, Leukapheresis, Busulfan, Stem cell reinfusion
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
56 Years to 74 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Prostate Cancer
Interventions
PSA prostate cancer vaccine, therapeutic autologous dendritic cells
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Conditions
Neuroblastoma, Sarcoma, Rhabdomyosarcoma-Embryonal, Rhabdomyosarcoma- Alveolar, Neuroectodermal Tumors, Primitive, Peripheral
Interventions
Tumor Purged/CD25 Depleted Lymphocytes, Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine, rhIL-7, Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Months to 35 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Breast Cancer, Metastatic Breast Cancer
Interventions
tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
Joseph Baar, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
2
States / cities
Cleveland, Ohio • Pittsburgh, Pennsylvania
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
Interventions
DC/AML Fusion Vaccine, T-Cell Therapy, Decitabine, Venetoclax, GM-CSF
Biological · Drug
Lead sponsor
David Avigan
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Glioblastoma Multiforme
Interventions
Autologous Dendritic Cell, Temozolomide, Radiotherapy, Dendritic Cell Vaccine
Biological · Drug · Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Endometrial Cancer, Cancer of Endometrium, Carcinoma of Endometrium, Endometrial Carcinoma
Interventions
AdHER2DC vaccine, Pembrolizumab, N-803, Lenvatinib, PATHWAY HER2 (4B5) assay
Biological · Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
autologous dendritic cell adenovirus CCL21 vaccine
Biological
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
West Los Angeles, California
Conditions
Brain Stem Glioma, Glioblastoma
Interventions
autologous dendritic cells
Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Los Angeles, California